Asia Deal Watch: Heartseed Licenses Lead Cell Therapy Candidate To Novo Nordisk
Executive Summary
Novo gets worldwide development and commercial rights except for Heartseed’s home market in Japan. LianBio unveils licensing partnerships with Lyra, Landos and Nanobiotix.
You may also be interested in...
Oncology Accelerates In China As Large Makers Hunt For Assets
New regulatory measures shorten clinical trial approval times and usher in busy deal-making between large makers and smaller biotechs outside China.
Amgen Wins World-First Lumakras Approval, Faces Challenge Of COVID-Era Launch
Commercial EVP Murdo Gordon said launching sotorasib during the pandemic is a tougher challenge than encouraging doctors to screen lung cancer patients for KRAS G12C mutations and raising patient awareness.
Apellis' Empaveli Poised To Give Soliris A Run In PNH
The first targeted C3 therapy was approved by the US FDA for treatment-naïve patients as well as those switching from Alexion's Soliris or Ultomiris.